Satellos Bioscience (TSE:MSCL) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Satellos Bioscience is launching an overnight marketed public offering of its common shares to fund the advancement of its Phase 2 clinical development and cover general corporate expenses. The offering, led by Bloom Burton Securities Inc., is set to close around December 20, 2024, pending regulatory approvals.
For further insights into TSE:MSCL stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money